CN110691599B - 使用脂多糖的脑功能改善剂、食品和药品 - Google Patents
使用脂多糖的脑功能改善剂、食品和药品 Download PDFInfo
- Publication number
- CN110691599B CN110691599B CN201780091325.7A CN201780091325A CN110691599B CN 110691599 B CN110691599 B CN 110691599B CN 201780091325 A CN201780091325 A CN 201780091325A CN 110691599 B CN110691599 B CN 110691599B
- Authority
- CN
- China
- Prior art keywords
- brain
- lipopolysaccharide
- group
- pantoea
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003925 brain function Effects 0.000 title claims abstract description 15
- 239000002158 endotoxin Substances 0.000 title claims description 74
- 229920006008 lipopolysaccharide Polymers 0.000 title claims description 72
- 239000003795 chemical substances by application Substances 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title claims description 13
- 235000013305 food Nutrition 0.000 title abstract description 26
- 241000520272 Pantoea Species 0.000 claims abstract description 51
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 23
- 230000037396 body weight Effects 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 abstract description 25
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 14
- 238000009825 accumulation Methods 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000032683 aging Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- 210000000274 microglia Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 5
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 241000588912 Pantoea agglomerans Species 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 239000005417 food ingredient Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000004676 glycans Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 feed Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-105133 | 2017-05-28 | ||
| JP2017105133A JP6998133B2 (ja) | 2017-05-28 | 2017-05-28 | リポ多糖を用いた脳機能改善剤、食品及び医薬品 |
| PCT/JP2017/043429 WO2018220886A1 (ja) | 2017-05-28 | 2017-12-04 | リポ多糖を用いた脳機能改善剤、食品及び医薬品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110691599A CN110691599A (zh) | 2020-01-14 |
| CN110691599B true CN110691599B (zh) | 2023-05-02 |
Family
ID=64455394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780091325.7A Active CN110691599B (zh) | 2017-05-28 | 2017-12-04 | 使用脂多糖的脑功能改善剂、食品和药品 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11278564B2 (enExample) |
| EP (1) | EP3643314B1 (enExample) |
| JP (2) | JP6998133B2 (enExample) |
| KR (2) | KR20220025912A (enExample) |
| CN (1) | CN110691599B (enExample) |
| BR (1) | BR112019024953A2 (enExample) |
| IL (1) | IL270936B2 (enExample) |
| WO (1) | WO2018220886A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6998133B2 (ja) * | 2017-05-28 | 2022-01-18 | 自然免疫制御技術研究組合 | リポ多糖を用いた脳機能改善剤、食品及び医薬品 |
| JP2023549503A (ja) * | 2020-11-13 | 2023-11-27 | ナショナル ヘルス リサーチ インスティチューツ | アミロイド原性疾患を処置する方法 |
| JP7679216B2 (ja) * | 2021-04-07 | 2025-05-19 | 有限会社バイオメディカルリサーチグループ | リポ多糖製造方法、リポ多糖、及びその配合物 |
| AU2022464309A1 (en) * | 2022-06-22 | 2025-01-23 | Biomedical Research Group Inc. | Prophylactic drug and therapeutic drug for diabetes-associated dementia |
| KR102555274B1 (ko) | 2022-12-03 | 2023-07-13 | 김환배 | 분리형 측면 미세먼지 집진휀스로 세척이 용이한 고기구이기 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106714827A (zh) * | 2014-10-02 | 2017-05-24 | 日东电工株式会社 | 经皮给药用疫苗药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4026722B2 (ja) | 2003-09-26 | 2007-12-26 | 源一郎 杣 | 植物発酵エキス、植物発酵エキス末及び該植物発酵エキス配合物 |
| JP2016193865A (ja) | 2015-03-31 | 2016-11-17 | キリン株式会社 | ミクログリア貪食活性亢進のための組成物及びミクログリア貪食活性亢進作用の予測方法 |
| JP6780240B2 (ja) | 2015-12-11 | 2020-11-04 | 株式会社リコー | 制御装置、液体を吐出する装置、印刷物の生産方法及びプログラム |
| JP6998133B2 (ja) * | 2017-05-28 | 2022-01-18 | 自然免疫制御技術研究組合 | リポ多糖を用いた脳機能改善剤、食品及び医薬品 |
-
2017
- 2017-05-28 JP JP2017105133A patent/JP6998133B2/ja active Active
- 2017-12-04 BR BR112019024953-2A patent/BR112019024953A2/pt not_active Application Discontinuation
- 2017-12-04 KR KR1020227004771A patent/KR20220025912A/ko not_active Ceased
- 2017-12-04 KR KR1020197038343A patent/KR20200011490A/ko not_active Ceased
- 2017-12-04 CN CN201780091325.7A patent/CN110691599B/zh active Active
- 2017-12-04 EP EP17911728.8A patent/EP3643314B1/en active Active
- 2017-12-04 WO PCT/JP2017/043429 patent/WO2018220886A1/ja not_active Ceased
- 2017-12-04 US US16/617,540 patent/US11278564B2/en active Active
- 2017-12-04 IL IL270936A patent/IL270936B2/en unknown
-
2021
- 2021-07-16 JP JP2021117563A patent/JP2021169506A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106714827A (zh) * | 2014-10-02 | 2017-05-24 | 日东电工株式会社 | 经皮给药用疫苗药物组合物 |
Non-Patent Citations (4)
| Title |
|---|
| A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway;Masahiro Fukasaka等;《pone》;20150515;全文 * |
| A mixture of Salacia oblonga extract and IP-PA1 reduces fasting plasma glucose (FPG) and low-density lipoprotein (LDL) cholesterol levels;Kazue Nakata等;《Nutrition Research and Practice》;20111231;全文 * |
| Effect of Lipopolysaccharide Derived from Pantoea agglomerans on the Phagocytic Activity of Amyloid β by Primary Murine Microglial Cells;YUTARO KOBAYASHI等;《ANTICANCER RESEARCH》;20161231;第3693-3698页 * |
| Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology;Jean-Philippe Michaud等;《PNAS》;20130129;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11278564B2 (en) | 2022-03-22 |
| IL270936B1 (en) | 2023-06-01 |
| JP6998133B2 (ja) | 2022-01-18 |
| WO2018220886A1 (ja) | 2018-12-06 |
| CN110691599A (zh) | 2020-01-14 |
| BR112019024953A2 (pt) | 2020-06-23 |
| JP2018199643A (ja) | 2018-12-20 |
| IL270936A (en) | 2020-01-30 |
| IL270936B2 (en) | 2023-10-01 |
| US20200179436A1 (en) | 2020-06-11 |
| EP3643314A1 (en) | 2020-04-29 |
| KR20220025912A (ko) | 2022-03-03 |
| JP2021169506A (ja) | 2021-10-28 |
| EP3643314A4 (en) | 2021-04-07 |
| EP3643314C0 (en) | 2023-08-30 |
| EP3643314B1 (en) | 2023-08-30 |
| KR20200011490A (ko) | 2020-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110691599B (zh) | 使用脂多糖的脑功能改善剂、食品和药品 | |
| JP7153950B2 (ja) | 神経発達障害療法 | |
| US11542468B2 (en) | Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases and use thereof | |
| JP7503179B2 (ja) | インスリン抵抗性改善用組成物 | |
| CN103402524A (zh) | 用于改善认知功能的组合剂 | |
| ES2208330T3 (es) | Composiciones para modular la respuesta nmune y para el tratamiento de la enfermedad inflamatoria. | |
| WO2024106716A1 (ko) | 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물 | |
| JP5769912B2 (ja) | 認知障害を伴う疾患又は状態の予防又は治療用の組成物 | |
| ES2973249T3 (es) | Composición que comprende cepa de Agathobaculum sp. como ingrediente efectivo para la prevención, alivio o tratamiento del trastorno del espectro autista | |
| JP7144052B2 (ja) | 掻痒性皮膚疾患の予防又は治療薬 | |
| EP3789023A1 (en) | Composition for preventing or treating cognitive disorder-associated diseases, containing mumefural | |
| HK40015331B (en) | Brain function-improving agent, food, and medicine using lipopolysaccharide | |
| US6652866B1 (en) | Method for treating diseases of fungal, yeast, and prion protein etiology | |
| HK40015331A (en) | Brain function-improving agent, food, and medicine using lipopolysaccharide | |
| US20240115530A1 (en) | Administration of baiba to increase benefit of losing weight of intermittent fasting | |
| JP7682509B1 (ja) | 認知機能の維持用、向上用又は改善用の組成物、飲食物、飼料及び医薬、認知症の予防薬及び治療薬、並びに脳疲労の予防用又は改善用の組成物、飲食物、飼料及び医薬 | |
| US20220096415A1 (en) | Composition for Improving Cognitive Function | |
| JP7181695B2 (ja) | 抗認知症剤及び短期記憶障害改善／抑制剤 | |
| EP4039329A1 (en) | Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein | |
| WO1999011266A1 (en) | Multiple sclerosis remedies | |
| CN114984034A (zh) | 一种寡糖类化合物的应用 | |
| JP2011213700A (ja) | 認知症改善用組成物 | |
| WO2019146652A1 (ja) | 抗ｉ型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善／抑制剤 | |
| JP2020176111A (ja) | アルツハイマー型認知症予防・治療用組成物、アミロイドβオリゴマー神経毒性低減用組成物 | |
| JP2018008895A (ja) | 認知機能低下抑制又は予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015331 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |